4-[4-(3-chlorophenyl)-2-ethyl-1,3-thiazol-5-yl]-N-[(1S)-1-phenylethyl]-pyridin-2-ylamine hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[4-(3-chlorophenyl)-2-ethyl-1,3-thiazol-5-yl]-N-[(1S)-1-phenylethyl]-pyridin-2-ylamine hydrochloride
• 英文别名: 4-[4-(3-chlorophenyl)-2-ethyl-1,3-thiazol-5-yl]-N-[(1S)-1-phenylethyl]-2-pyridylamine hydrochloride；4-[4-(3-chlorophenyl)-2-ethyl-1,3-thiazol-5-yl]-N-[(1S)-1-phenylethyl]pyridin-2-amine;hydrochloride
• 化学式: C₂₄H₂₂ClN₃S*ClH
• 分子量: 456.439
• InChiKey: MXQSLDHZBOABHM-NTISSMGPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.68
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-ethyl-5-(2-fluoro-pyridin-4-yl)-4-(3-chlorophenyl)-1,3-thiazole 、 (S)-(-)- α-甲基苄胺 在 盐酸 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以56%的产率得到4-[4-(3-chlorophenyl)-2-ethyl-1,3-thiazol-5-yl]-N-[(1S)-1-phenylethyl]-pyridin-2-ylamine hydrochloride
  参考文献：
  名称：

  EP1364949

  摘要：

  公开号：

文献信息

• MEDICINAL COMPOSITIONS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1402900A1

  公开（公告）日：2004-03-31

  The present invention relates to an agent for the prophylaxis or treatment of pain, an agent for suppressing activation of osteoclast, and an inhibitor of osteoclast formation, which contains a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor.

  本发明涉及一种用于预防或治疗疼痛的药剂，一种用于抑制破骨细胞活化的药剂，以及一种包含p38 MAP激酶抑制剂和/或TNF-α产生抑制剂的破骨细胞形成抑制剂。
• Jnk inhibitor
  申请人：——

  公开号：US20040063946A1

  公开（公告）日：2004-04-01

  The present invention relates to a c-Jun N-terminal kinase inhibitor containing an azole compound (I) substituted by a nitrogen-containing aromatic group having substituent(s)(except a compound represented by the formula: 1 ) or a salt thereof or a prodrug thereof.

  本发明涉及一种含有氮取代芳香基团（除了公式1所代表的化合物）取代的咪唑衍生物（I）的c-Jun N-末端激酶抑制剂，或其盐或前药。
• JNK inhibitor
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07199124B2

  公开（公告）日：2007-04-03

  The present invention relates to a c-Jun N-terminal kinase inhibitor containing an azole compound (I) substituted by a nitrogen-containing aromatic group having substituent(s)(except a compound represented by the formula: ) or a salt thereof or a prodrug thereof.

  本发明涉及一种含有氮取代芳香基团取代物（除了公式所表示的化合物之外）或其盐或其前药的氮唑化合物（I）的c-Jun N末端激酶抑制剂。
• JNK INHIBITOR
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1364949A1

  公开（公告）日：2003-11-26

  The present invention relates to a c-Jun N-terminal kinase inhibitor containing an azole compound (I) substituted by a nitrogen-containing aromatic group having substituent(s)(except a compound represented by the formula: ) or a salt thereof or a prodrug thereof.

  本发明涉及一种c-Jun N-末端激酶抑制剂，它含有被含氮芳香基团取代的唑类化合物(I)(由式...代表的化合物除外)或其盐或其原药： )或其盐或其原药。
• Therapeutic methods for type I diabetes
  申请人：Davis J. Roger

  公开号：US20060223807A1

  公开（公告）日：2006-10-05

  The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying β-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.

  本发明涉及 I 型糖尿病的治疗和预防。更具体地说，本发明涉及通过抑制 JNK2、选择性抑制 JNK2 或抑制 MAPK9 基因或基因产物的表达来治疗或防止机体免疫系统破坏 β 细胞（即胰岛中的胰岛素分泌细胞）的化合物。在一个实施方案中，本发明考虑诊断、鉴定、生产和使用调节 MAPK9 基因表达或 MAPK9 基因产物活性的化合物，包括但不限于 JNK2、编码 MAPK9 的核酸及其同源物、类似物和缺失物，以及反义、核糖酶、三重螺旋、抗体和多肽分子以及无机小分子。本发明考虑了此类化合物的各种药物制剂和给药途径。